In Vitro α-Amylase and α-Glucosidase Inhibitory and Antioxidant Activities of the Crude Extract and Solvent Fractions of Hagenia abyssinica Leaves

被引:25
作者
Kifle, Zemene Demelash [1 ]
Debeb, Simachew Gidey [2 ]
Belayneh, Yaschilal Muche [3 ]
机构
[1] Univ Gondar, Sch Pharm, Dept Pharmacol, Coll Med & Hlth Sci, Gondar, Ethiopia
[2] Univ Gondar, Sch Pharm, Dept Clin Pharm, Coll Med & Hlth Sci, Gondar, Ethiopia
[3] Wollo Univ, Dept Pharm, Coll Med & Hlth Sci, Dessie, Ethiopia
关键词
TYPE-2; DIABETES-MELLITUS; CONSTITUENTS; IDENTIFICATION; POTENTIALS;
D O I
10.1155/2021/6652777
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background. The leaves of Hagenia abyssinica have been used in the management of diabetes mellitus in Ethiopian folk medicine. Thus, this study is aimed at investigating the in vitro alpha-amylase and alpha-glucosidase inhibitory and antioxidant activities of the crude extract and solvent fractions of H. abyssinica leaves. Methods. The in vitro alpha-amylase and alpha-glucosidase inhibitory and antioxidant activities of the plant extract were assessed using 3,5-dinitrosalicylic acid (DNSA), p-nitro-phenyl-a-D glucopyranoside (p-NPG), and 1,1-diphenyl-2-picrylhydrazyl (DPPH) assays, respectively. Each value of percent inhibition of alpha-amylase, alpha-glucosidase, and DPPH scavenging effect was presented as means +/- SEM (n=3). Results. The alpha-amylase inhibitory activity of the crude extract and solvent fractions was found to be concentration-dependent. The strongest activity was exhibited by the crude extract at the highest concentration with a percentage inhibition of 74.52% (IC50, 14.52 mu g/ml) followed by water fraction 68.24% (IC50, 16.31 mu g/ml), ethyl acetate fraction 61.57% (IC50, 18.73 mu g/ml), and chloroform fraction 56.87% (IC50, 21.57 mu g/ml) of H. abyssinica leaves. In the alpha-glucosidase inhibition assay, the maximum activity was exhibited by the aqueous fraction 62.54% (IC50, 11.67 mu g/ml) followed by ethyl acetate fraction 54.97% (IC50, 15.89 mu g/ml), crude extract 46.79% (IC50, >16.5 mu g/ml), and chloroform fraction 36.44% (IC50, >16.5 mu g/ml). In the antioxidant assay, the crude extract exhibited the highest antioxidant activity 86.36% (IC50, 10.25 mu g/ml) followed by water fraction 78.59% (IC50, 13.86 mu g/ml), ethyl acetate fraction 71.58% (IC50, 16.34 mu g/ml), and chloroform fraction 63.65% (IC50, 18.83 mu g/ml). Conclusion. This study has revealed that H. abyssinica leaves possess noticeable in vitro alpha-amylase and alpha-glucosidase inhibitory and antioxidant activities.
引用
收藏
页数:9
相关论文
共 53 条
[1]  
Abiyu Enyew Abiyu Enyew, 2014, Current Research Journal of Biological Sciences, V6, P154
[2]   Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity [J].
Ali, Khawla F. ;
Shukla, Alpana P. ;
Aronne, Louis J. .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (01) :27-34
[3]   Hypoglycemic and antilipidemic properties of kombucha tea in alloxan-induced diabetic rats [J].
Aloulou, Ahmed ;
Hamden, Khaled ;
Elloumi, Dhouha ;
Ali, Madiha Bou ;
Hargafi, Khaoula ;
Jaouadi, Bassem ;
Ayadi, Fatma ;
Elfeki, Abdelfattah ;
Ammar, Emna .
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2012, 12
[4]   Ethnomedicinal uses of Hagenia abyssinica (Bruce) JF Gmel. among rural communities of Ethiopia [J].
Assefa, Biruktayet ;
Glatzel, Gerhard ;
Buchmann, Christine .
JOURNAL OF ETHNOBIOLOGY AND ETHNOMEDICINE, 2010, 6
[5]   Ferulic acid and its therapeutic potential as a hormetin for age-related diseases [J].
Barone, Eugenio ;
Calabrese, Vittorio ;
Mancuso, Cesare .
BIOGERONTOLOGY, 2009, 10 (02) :97-108
[6]  
BEAUCHAMP C, 1970, J BIOL CHEM, V245, P4641
[7]  
Beentje H., 1994, KENYA TREES SHRUBS L
[8]   EVALUATION OF ANTI-DIABETIC ACTIVITY OF LEAVES OF ACTINODAPHNE HOOKERI MEISSN [J].
Bhaskaran, Meera ;
Mruthunjaya, K. ;
Manjula, S. N. ;
Rajan, Dhanya .
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2019, 10 (01) :83-96
[9]   Surviving antioxidant supplements [J].
Bjelakovic, Goran ;
Gluud, Christian .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (10) :742-743
[10]  
Bruchlausen F.V, 1979, ARCH PHARM, V308, P27